Hepatitis B News and Research

Latest Hepatitis B News and Research

Working better with Aboriginal clients: addressing sexual health, HIV and hepatitis C

Improving access to sexual health and related services for Aboriginal and Torres Strait Islander people living in NSW will be among the issues discussed at a workshop coordinated by the University of New South Wales (UNSW).

19 Aug 2008

FDA approves Gilead's antiretroviral Viread for hepatitis B

Gilead Sciences on Monday announced that it has received FDA approval to market its antiretroviral drug Viread as a hepatitis B treatment, the AP/International Herald Tribune reports (AP/International Herald Tribune, 8/12).

13 Aug 2008

NanoBio vaccine for hepatitis B shows promise

Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an estimated 1 million deaths globally each year.

13 Aug 2008

Viread approved for chronic hepatitis B

The FDA has approved Viread (tenofovir disoproxil fumarate) as a treatment option for adults with chronic hepatitis B, a serious liver disease.

11 Aug 2008

Technological crystal ball boosts AIDS survival

A cure for the virus that causes AIDS may still be beyond our grasp, but European researchers have developed a predictive software system for HIV that could help extend the lives of victims of the killer disease.

11 Aug 2008

Early treatment key to combating hepatitis C virus

Canadian researchers have shown that patients who receive early treatment for Hepatitis C virus (HCV) within the first months following an infection, develop a rapid poly-functional immune response against HCV similar to when infection is erradicted spontaneously, according to a new study published in the Journal of Virology.

10 Aug 2008

Targeted action on HIV and tuberculosis needed to reach drug users

Health and criminal justice authorities need to provide targeted services to drug users, especially those who inject drugs, to prevent and treat tuberculosis (TB) and HIV. TB is a major cause of death for people living with HIV, but drug users who are HIV-positive face stigma, discrimination and barriers to accessing life-saving treatments.

4 Aug 2008

New studies examine use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C

Two new studies examine the use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C. The reports appear in the August issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

31 Jul 2008

Warfarin may prevent liver failure in hepatitis C

The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.

31 Jul 2008

Structure and composition of hepatitis B virus now mapped

Using a newly developed method, Utrecht University researchers have mapped the structure and composition of the hepatitis B virus.

28 Jul 2008

Researchers disprove long-standing belief about HIV treatment

Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated with a combination of drugs known as the 'cocktail.'

27 Jul 2008

U.S. tightens visas with vaccine requirements

New vaccine requirements will affect anyone who is applying for an immigrant visa for entry into the U.S. and anyone seeking adjustment of status for permanent residence.

23 Jul 2008

Could arthritis wonder drugs provide clues for all disease?

Drugs that have helped treat millions of rheumatoid arthritis sufferers may hold the key to many more medical conditions, including atherosclerosis - a leading cause of heart disease - says the researcher who jointly invented and developed them.

From The University of Manchester 17 Jul 2008

EpiCept and GNI partner to develop anti-viral hepatitis drug in Asia

GNI Ltd and EpiCept Corporation have announced that they have reached agreement to develop a new therapeutic drug, EP1013, in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis. EpiCept will retain the rights in the rest of the world. GNI’s wholly owned subsidiary, Shanghai Genomics, will start preparation for pre-IND and clinical development in China immediately.

17 Jul 2008

FDA approves Energex Systems non-drug therapy for HIV research

Energex Systems, Inc. announced today that it has been granted approval from the Federal Food and Drug Administration (FDA) to utilize its experimental HemoModulation therapy in a clinical trial of HIV infected patients. The purpose of the study will be to demonstrate safety and monitor viral load changes in patients who are not yet eligible for antiviral drug therapy.

14 Jul 2008

Enzyme may explain how hepatitis C infection causes fatty liver

A key enzyme may explain how hepatitis C infection causes fatty liver - a buildup of excess fat in the liver, which can lead to life-threatening diseases such as cirrhosis and liver cancer, report University of Pittsburgh Graduate School of Public Health and School of Medicine researchers.

10 Jul 2008

Disease-detecting lab-on-a-chip

Detecting food-borne diseases such as campylobacter and salmonella long before they enter the food chain would help ensure that the dinner on your table is safe to eat.

1 Jul 2008

Fatty liver disease may raise heart disease risk in overweight, obese kids

A fatty liver disease that is not well-known in overweight and obese children may be a precursor of cardiovascular disease, researchers reported in Circulation: Journal of the American Heart Association.

30 Jun 2008

Penn researchers propose major changes to informed consent for transplantation

University of Pennsylvania School of Medicine physicians and bioethicists are calling for a new, more standardized way for patients in need of organ transplants to be informed of the risks they face. If adopted, their policy recommendations could promote greater equity in how organs are allocated while restricting patients' abilities to "cherry-pick" the best organs.

26 Jun 2008

State policies have a significant impact on drug treatment programs

State policies have a significant impact on the services performed by substance abuse treatment programs, and could play a key role in efforts to expand the use of research-based "comprehensive" treatment approaches, reports a study in the June issue of the Journal of Substance Abuse Treatment (JSAT).

25 Jun 2008